{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.304","value":"5.81"},{"groupId":"OG001","spread":"9.371","value":"9.04"}]}],"title":"Peginterferon alfa-2a dose reduction, n=163, 193"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.219","value":"11.16"},{"groupId":"OG001","spread":"9.830","value":"12.58"}]}],"title":"Ribavirin dose reduction, n=63, 162"}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"ITT Population. Only those participants with dose reductions were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase","type":"SECONDARY","unitOfMeasure":"weeks"}